NCT07548489
Phenobarbital for Agitated Delirium
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Stopped Withdrawn before enrolling Sponsor's reason: Not approved by IRB Show 4 more changesShow less
- Enrollment target: estimated 150 to confirmed 0
- Eligibility criteria expanded, about 5 words
- Site contact updated
- Publications: details revised at 1 of 1 entry
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
Endpoints
Primary
Secondary (3)
Arms and interventions
In alternating months, patients starting therapy for agitated delirium will be assigned to either a phenobarbital regimen or a conventional antipsychotic-based regimen. Patients assigned to Phenobarbital Therapy will receive this drug according to a validated protocol similar to that in use for patients with alcohol withdrawal. Additional "rescue" medications including dexmedetomidine will be available as needed.
In alternating months, patients starting therapy for agitated delirium will be assigned to either a phenobarbital regimen or a conventional antipsychotic-based regimen. Patients assigned to Conventional Therapy will receive antipsychotics as the primary medications for managing their agitation. Additional "rescue" medications including antipsychotics and dexmedetomidine will be available as needed.
Drugs: Phenobarbital, Conventional therapy group
Sites
1 site in 1 country
- Duke Regional HospitalDurham, North Carolina, United States